Financial Performance - The net profit attributable to shareholders for the reporting period is expected to be 99.84 million yuan, an increase of 22.49% compared to 81.51 million yuan in the same period last year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be 81.54 million yuan, up 66.10% from 49.09 million yuan in the previous year[3]. - The increase in net profit is primarily due to enhanced market expansion efforts, leading to increased operating revenue compared to the previous year[4]. Government Subsidies - The company recognized government subsidies related to assets amounting to 17.37 million yuan as regular gains in 2023, which contributed to the profit increase[5]. Financial Reporting - The financial data provided is preliminary and has not been audited by an accounting firm, with final figures to be disclosed in the annual report[6].
星昊医药(430017) - 2023 Q4 - 年度业绩预告